Alnylam Pharmaceuticals
ALNY
#685
Rank
A$52.07 B
Marketcap
A$390.08
Share price
1.35%
Change (1 day)
-20.97%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

P/S ratio for Alnylam Pharmaceuticals (ALNY)

P/S ratio as of July 2026 (TTM): 8.37

According to Alnylam Pharmaceuticals 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 33.4. At the end of 2026 the company had a P/S ratio of 9.82.

P/S ratio history for Alnylam Pharmaceuticals from 2004 to 2026

PS ratio at the end of each year

Year P/S ratio Change
20269.82-31.03%
202514.24.27%
202413.73.91%
202313.1-53.38%
202228.217.32%
202124.0-21.59%
202030.6-47.89%
201958.8-40.29%
201898.5-29.73%
2017140105.69%
201668.1-65.05%
201519531.6%
201414870.45%
201386.9505.26%
201214.4241.19%
20114.210.83%
20104.17-43.09%
20097.33-31.15%
200810.7-54.28%
200723.3-20.88%
200629.4-34.68%
200545.133.85%
200433.7

P/S ratio for similar companies or competitors

Company P/S ratio P/S ratio differencediff. Country
Novartis
NVS
5.25-37.33%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
1.87-77.64%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
4.58-45.27%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
0.7676-90.83%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
1.52-81.84%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
2.09-74.99%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
19.7 134.80%๐Ÿ‡บ๐Ÿ‡ธ USA